id	sid	eid	entity	type
dpc-1882	1	1	today	DATE
dpc-1882	1	2	claudio conforti	PERSON
dpc-1882	1	3	harald kittler melanoma:	ORG
dpc-1882	1	4	chryssoula papageorgiou	PERSON
dpc-1882	1	5	zoe apalla	PERSON
dpc-1882	1	6	sofia-magdalini manoli	PERSON
dpc-1882	1	7	vincenzo de falco	PERSON
dpc-1882	1	8	stefania napolitano	PERSON
dpc-1882	1	9	luigi pio guerrera	PERSON
dpc-1882	1	10	troiani	NORP
dpc-1882	1	11	pietro quaglino	PERSON
dpc-1882	1	12	paolo	PERSON
dpc-1882	1	13	luca tonella	PERSON
dpc-1882	1	14	marco rubatto	PERSON
dpc-1882	1	15	simone ribero	PERSON
dpc-1882	1	16	maria teresa	PERSON
dpc-1882	1	17	1885	DATE
dpc-1882	2	1	giuseppe argenziano	PERSON
dpc-1882	2	2	md dermatology unit	ORG
dpc-1882	2	3	university of campania luigi vanvitelli	ORG
dpc-1882	2	4	naples	GPE
dpc-1882	3	1	h. peter soyer	PERSON
dpc-1882	3	2	md	GPE
dpc-1882	4	1	the university of queensland diamantina institute	ORG
dpc-1882	4	2	alexandra hospital prof	PERSON
dpc-1882	5	1	paola queirolo	PERSON
dpc-1882	5	2	md	GPE
dpc-1882	5	3	the “divisione di oncologia medica del melanoma	ORG
dpc-1882	5	4	istituto europeo di oncologia	PERSON
dpc-1882	5	5	al contributo di melanoma	PERSON
dpc-1882	5	6	today	DATE
dpc-1882	5	7	claudio conforti	PERSON
dpc-1882	5	8	harald kittler melanoma:	ORG
dpc-1882	5	9	chryssoula papageorgiou	PERSON
dpc-1882	5	10	zoe apalla	PERSON
dpc-1882	5	11	sofia-magdalini manoli	PERSON
dpc-1882	5	12	vincenzo de falco	PERSON
dpc-1882	5	13	stefania napolitano	PERSON
dpc-1882	5	14	luigi pio guerrera	PERSON
dpc-1882	5	15	troiani	NORP
dpc-1882	5	16	pietro quaglino	PERSON
dpc-1882	5	17	paolo	PERSON
dpc-1882	5	18	luca tonella	PERSON
dpc-1882	5	19	marco rubatto	PERSON
dpc-1882	5	20	simone ribero	PERSON
dpc-1882	5	21	maria teresa	PERSON
dpc-1882	5	22	1885	DATE
dpc-1882	6	1	giuseppe argenziano	PERSON
dpc-1882	6	2	md dermatology unit	ORG
dpc-1882	6	3	university of campania luigi vanvitelli	ORG
dpc-1882	6	4	naples	GPE
dpc-1882	7	1	h. peter soyer	PERSON
dpc-1882	7	2	md	GPE
dpc-1882	8	1	the university of queensland diamantina institute	ORG
dpc-1882	8	2	alexandra hospital prof	PERSON
dpc-1882	9	1	paola queirolo	PERSON
dpc-1882	9	2	md	GPE
dpc-1882	9	3	the “divisione di oncologia medica del melanoma	ORG
dpc-1882	9	4	istituto europeo di oncologia	PERSON
dpc-1882	9	5	al contributo di melanoma	PERSON
dpc-1882	9	6	today	DATE
dpc-1882	9	7	claudio conforti	PERSON
dpc-1882	9	8	harald kittler melanoma:	ORG
dpc-1882	9	9	chryssoula papageorgiou	PERSON
dpc-1882	9	10	zoe apalla	PERSON
dpc-1882	9	11	sofia-magdalini manoli	PERSON
dpc-1882	9	12	vincenzo de falco	PERSON
dpc-1882	9	13	stefania napolitano	PERSON
dpc-1882	9	14	luigi pio guerrera	PERSON
dpc-1882	9	15	troiani	NORP
dpc-1882	9	16	pietro quaglino	PERSON
dpc-1882	9	17	paolo	PERSON
dpc-1882	9	18	luca tonella	PERSON
dpc-1882	9	19	marco rubatto	PERSON
dpc-1882	9	20	simone ribero	PERSON
dpc-1882	9	21	maria teresa	PERSON
dpc-1882	10	1	h. peter soyer	PERSON
dpc-1882	10	2	md	GPE
dpc-1882	11	1	the university of queensland diamantina institute	ORG
dpc-1882	11	2	alexandra hospital prof	PERSON
dpc-1882	12	1	paola queirolo	PERSON
dpc-1882	12	2	md	GPE
dpc-1882	12	3	the “divisione di oncologia medica del melanoma	ORG
dpc-1882	12	4	istituto europeo di oncologia	PERSON
dpc-1882	14	1	2021;11(s1	CARDINAL
dpc-1882	14	2	1	CARDINAL
dpc-1882	14	3	stefania napolitano1	PERSON
dpc-1882	14	4	luigi pio guerrera1	PERSON
dpc-1882	14	5	troiani1	ORG
dpc-1882	14	6	università degli studi della campania	ORG
dpc-1882	14	7	luigi vanvitelli	PERSON
dpc-1882	14	8	napoli	GPE
dpc-1882	14	9	italy	GPE
dpc-1882	14	10	de falco	PERSON
dpc-1882	14	11	napolitano s	PERSON
dpc-1882	14	12	guerrera lp	PERSON
dpc-1882	14	13	troiani t.	PERSON
dpc-1882	16	1	july 14, 2021	DATE
dpc-1882	17	1	july 2021	DATE
dpc-1882	17	2	2021	CARDINAL
dpc-1882	17	3	de falco et al	PERSON
dpc-1882	22	1	teresa troiani	PERSON
dpc-1882	22	2	md	GPE
dpc-1882	22	3	phd	GPE
dpc-1882	22	4	università della campania	ORG
dpc-1882	22	5	luigi vanvitelli	PERSON
dpc-1882	22	6	s. pansini 5, 80131	ORG
dpc-1882	22	7	napoli	GPE
dpc-1882	22	8	italy	GPE
dpc-1882	23	1	00390815666728	DATE
dpc-1882	25	1	pt1b	GPE
dpc-1882	26	1	1mm	QUANTITY
dpc-1882	26	2	pembrolizumab	PERSON
dpc-1882	28	1	the dpc journal special	ORG
dpc-1882	28	2	today	DATE
dpc-1882	29	1	h. peter soyer	PERSON
dpc-1882	29	2	md	GPE
dpc-1882	30	1	the university of queensland diamantina institute	ORG
dpc-1882	30	2	alexandra hospital prof	PERSON
dpc-1882	31	1	paola queirolo	PERSON
dpc-1882	31	2	md	GPE
dpc-1882	31	3	the “divisione di oncologia medica del melanoma	ORG
dpc-1882	31	4	istituto europeo di oncologia	PERSON
dpc-1882	31	5	2	CARDINAL
dpc-1882	32	1	1	CARDINAL
dpc-1882	33	1	about 50%	PERCENT
dpc-1882	33	2	15	CARDINAL
dpc-1882	33	3	600	CARDINAL
dpc-1882	33	4	2	CARDINAL
dpc-1882	34	1	the american joint committee	ORG
dpc-1882	34	2	3	CARDINAL
dpc-1882	38	1	few years ago	DATE
dpc-1882	38	2	4	CARDINAL
dpc-1882	39	1	pembrolizumab	PERSON
dpc-1882	39	2	4	CARDINAL
dpc-1882	40	1	5	CARDINAL
dpc-1882	42	1	2015	DATE
dpc-1882	42	2	18071	DATE
dpc-1882	42	3	10mg/kg	QUANTITY
dpc-1882	42	4	up to 3 years	DATE
dpc-1882	43	1	6	CARDINAL
dpc-1882	44	1	5	CARDINAL
dpc-1882	45	1	ipilimumab	PERSON
dpc-1882	45	2	the european medicines	ORG
dpc-1882	45	3	ema	ORG
dpc-1882	46	1	3mg/kg vs ipilimumab	PRODUCT
dpc-1882	46	2	up to 1 year	DATE
dpc-1882	46	3	81.3%	PERCENT
dpc-1882	48	1	4-year	DATE
dpc-1882	48	2	52.4%	PERCENT
dpc-1882	48	3	24.1%	PERCENT
dpc-1882	48	4	0.71	CARDINAL
dpc-1882	49	1	8	CARDINAL
dpc-1882	50	1	14.4%	PERCENT
dpc-1882	50	2	3-5	CARDINAL
dpc-1882	51	1	3.5-year	DATE
dpc-1882	51	2	59.8%	PERCENT
dpc-1882	51	3	41.4%	PERCENT
dpc-1882	51	4	0.59	CARDINAL
dpc-1882	52	1	9	CARDINAL
dpc-1882	53	1	pembrolizumab	PERSON
dpc-1882	53	2	1 year	DATE
dpc-1882	53	3	up to 3 years	DATE
dpc-1882	53	4	0.74	CARDINAL
dpc-1882	54	1	10	CARDINAL
dpc-1882	55	1	pembrolizumab	PERSON
dpc-1882	55	2	ema	ORG
dpc-1882	56	1	ipilimumab	PERSON
dpc-1882	57	1	first	ORDINAL
dpc-1882	57	2	german	NORP
dpc-1882	57	3	nivolumab+ipilimumab	PERSON
dpc-1882	58	1	0.23	CARDINAL
dpc-1882	58	2	28.4 months	DATE
dpc-1882	58	3	11	CARDINAL
dpc-1882	59	1	12	CARDINAL
dpc-1882	61	1	mek	ORG
dpc-1882	63	1	150 mg	QUANTITY
dpc-1882	63	2	daily	DATE
dpc-1882	63	3	mek	ORG
dpc-1882	63	4	2 mg	QUANTITY
dpc-1882	63	5	daily	DATE
dpc-1882	64	1	3-years	DATE
dpc-1882	64	2	58%	PERCENT
dpc-1882	64	3	39%	PERCENT
dpc-1882	65	1	13	CARDINAL
dpc-1882	69	1	2021;11(s1	CARDINAL
dpc-1882	69	2	3	CARDINAL
dpc-1882	70	1	3	CARDINAL
dpc-1882	70	2	41%	PERCENT
dpc-1882	74	1	first	ORDINAL
dpc-1882	74	2	ipilimumab	PERSON
dpc-1882	74	3	checkmate-238	ORG
dpc-1882	74	4	48 months	DATE
dpc-1882	74	5	78%	PERCENT
dpc-1882	74	6	77%	PERCENT
dpc-1882	74	7	0.87 p=0.315)[8	QUANTITY
dpc-1882	76	1	10	CARDINAL
dpc-1882	77	1	3-years	DATE
dpc-1882	77	2	86%	PERCENT
dpc-1882	77	3	77%	PERCENT
dpc-1882	77	4	0.57	CARDINAL
dpc-1882	78	1	13	CARDINAL
dpc-1882	79	1	2	CARDINAL
dpc-1882	80	1	second	ORDINAL
dpc-1882	81	1	14	CARDINAL
dpc-1882	81	2	german	NORP
dpc-1882	81	3	15	CARDINAL
dpc-1882	85	1	16	CARDINAL
dpc-1882	86	1	1mm	QUANTITY
dpc-1882	90	1	17	CARDINAL
dpc-1882	91	1	18	CARDINAL
dpc-1882	94	1	19	CARDINAL
dpc-1882	94	2	20	CARDINAL
dpc-1882	95	1	more than a year	DATE
dpc-1882	95	2	2-3 years	DATE
dpc-1882	96	1	few months	DATE
dpc-1882	98	1	6 months	DATE
dpc-1882	98	2	22	CARDINAL
dpc-1882	101	1	one	CARDINAL
dpc-1882	101	2	5-year	DATE
dpc-1882	101	3	iib	PRODUCT
dpc-1882	101	4	87%	PERCENT
dpc-1882	101	5	iic	PERSON
dpc-1882	101	6	82%	PERCENT
dpc-1882	101	7	93%	PERCENT
dpc-1882	102	1	checkmate-76k	ORG
dpc-1882	102	2	nivolumab	PERSON
dpc-1882	103	1	2023-24	DATE
dpc-1882	105	1	40%	PERCENT
dpc-1882	105	2	2 years	DATE
dpc-1882	105	3	40%	PERCENT
dpc-1882	105	4	3 years	DATE
dpc-1882	105	5	15-20%	PERCENT
dpc-1882	106	1	23	CARDINAL
dpc-1882	108	1	the last years	DATE
dpc-1882	108	2	6	CARDINAL
dpc-1882	108	3	2	CARDINAL
dpc-1882	108	4	4	CARDINAL
dpc-1882	109	1	19	CARDINAL
dpc-1882	111	1	39.7%	PERCENT
dpc-1882	111	2	4	CARDINAL
dpc-1882	112	1	20%	PERCENT
dpc-1882	112	2	dabrafenib+trametinib	PERSON
dpc-1882	112	3	47%	PERCENT
dpc-1882	112	4	nivolumab+ipilimumab	PERSON
dpc-1882	112	5	42.7%	PERCENT
dpc-1882	113	1	1 year	DATE
dpc-1882	113	2	84%	PERCENT
dpc-1882	113	3	75%	PERCENT
dpc-1882	113	4	2 years	DATE
dpc-1882	113	5	80%	PERCENT
dpc-1882	113	6	47%	PERCENT
dpc-1882	114	1	nivolumab+ipilimumab	PERSON
dpc-1882	114	2	about 2/3	CARDINAL
dpc-1882	114	3	99%	PERCENT
dpc-1882	114	4	2 years	DATE
dpc-1882	115	1	21%	PERCENT
dpc-1882	118	1	one	CARDINAL
dpc-1882	120	1	1	CARDINAL
dpc-1882	121	1	paulson kg	PERSON
dpc-1882	121	2	kim	PERSON
dpc-1882	121	3	the united states	GPE
dpc-1882	123	1	2020;156(1):5764	CARDINAL
dpc-1882	124	1	doi:10.1001	GPE
dpc-1882	126	1	2	CARDINAL
dpc-1882	126	2	giunta ef	PERSON
dpc-1882	126	3	de falco	PERSON
dpc-1882	126	4	napolitano s	PERSON
dpc-1882	128	1	adv med oncol	PERSON
dpc-1882	129	1	2020;12	CARDINAL
dpc-1882	130	1	pmid	PERSON
dpc-1882	130	2	32612709	CARDINAL
dpc-1882	131	1	3	CARDINAL
dpc-1882	131	2	balch cm	PERSON
dpc-1882	131	3	soong s-j	PERSON
dpc-1882	131	4	2009	DATE
dpc-1882	132	1	j clin oncol	PERSON
dpc-1882	133	1	2009;27(36):6199-6206	DATE
dpc-1882	135	1	19917835	DATE
dpc-1882	136	1	4	CARDINAL
dpc-1882	136	2	ives nj	PERSON
dpc-1882	141	1	28692949	CARDINAL
dpc-1882	142	1	5	CARDINAL
dpc-1882	142	2	michielin o	PERSON
dpc-1882	142	3	van akkooi acj	PERSON
dpc-1882	142	4	ascierto pa	GPE
dpc-1882	142	5	dummer r	ORG
dpc-1882	142	6	keilholz u	GPE
dpc-1882	142	7	esmo guidelines committee	ORG
dpc-1882	144	1	clinicalguidelines@esmo.org	CARDINAL
dpc-1882	144	2	ann oncol	PERSON
dpc-1882	145	1	2019;30(12):1884-1901	DATE
dpc-1882	147	1	31566661	CARDINAL
dpc-1882	148	1	6	CARDINAL
dpc-1882	148	2	grob j-j	PERSON
dpc-1882	149	1	new england journal of medicine	ORG
dpc-1882	150	1	2016;375(19):1845-1855	DATE
dpc-1882	152	1	27717298	DATE
dpc-1882	153	1	7	CARDINAL
dpc-1882	153	2	weber j	PERSON
dpc-1882	153	3	mandala m	PERSON
dpc-1882	153	4	del vecchio m	ORG
dpc-1882	155	1	new england journal of medicine	ORG
dpc-1882	156	1	2017;377(19):1824-1835	DATE
dpc-1882	158	1	28891423	CARDINAL
dpc-1882	159	1	8	CARDINAL
dpc-1882	159	2	ascierto pa	GPE
dpc-1882	159	3	del vecchio m	GPE
dpc-1882	159	4	mandalá m	PERSON
dpc-1882	160	1	238	CARDINAL
dpc-1882	160	2	4-year	DATE
dpc-1882	160	3	3	CARDINAL
dpc-1882	162	1	2020;21(11):1465	CARDINAL
dpc-1882	163	1	doi:10.1016	GPE
dpc-1882	163	2	9	CARDINAL
dpc-1882	163	3	cu	ORG
dpc-1882	163	4	mandala m	ORG
dpc-1882	165	1	new england journal of medicine	ORG
dpc-1882	166	1	2018;378(19):1789-1801	DATE
dpc-1882	168	1	29658430	DATE
dpc-1882	169	1	10	CARDINAL
dpc-1882	170	1	grossmann kf	PERSON
dpc-1882	171	1	hdi	ORG
dpc-1882	172	1	jco	PERSON
dpc-1882	173	1	2021;39(15_suppl):9501-9501	DATE
dpc-1882	175	1	11	DATE
dpc-1882	176	1	zimmer l	ORG
dpc-1882	176	2	livingstone e	GPE
dpc-1882	176	3	hassel jc	PERSON
dpc-1882	177	1	nivolumab	PERSON
dpc-1882	177	2	2	CARDINAL
dpc-1882	178	1	lancet	ORG
dpc-1882	180	1	doi:10.1016	GPE
dpc-1882	180	2	6736(20)30417	CARDINAL
dpc-1882	180	3	12	CARDINAL
dpc-1882	181	1	vecchio md	GPE
dpc-1882	182	1	ipi	ORG
dpc-1882	182	2	915	CARDINAL
dpc-1882	183	1	2021;81(13	CARDINAL
dpc-1882	184	1	13	CARDINAL
dpc-1882	187	1	new england journal of medicine	ORG
dpc-1882	188	1	2017;377(19):1813-1823	DATE
dpc-1882	191	1	14	CARDINAL
dpc-1882	192	1	thompson jf	PERSON
dpc-1882	192	2	cochran aj	PERSON
dpc-1882	195	1	28591523	DATE
dpc-1882	196	1	15	CARDINAL
dpc-1882	196	2	leiter u	PERSON
dpc-1882	196	3	stadler	ORG
dpc-1882	197	1	j clin oncol	PERSON
dpc-1882	198	1	2019;37(32):3000-3008	CARDINAL
dpc-1882	200	1	pmid	PERSON
dpc-1882	200	2	31557067	DATE
dpc-1882	201	1	16	CARDINAL
dpc-1882	202	1	gershenwald je	PERSON
dpc-1882	202	2	hess kr	PERSON
dpc-1882	202	3	the american joint committee	ORG
dpc-1882	202	4	eighth	ORDINAL
dpc-1882	204	1	2017;67(6):472-492	CARDINAL
dpc-1882	206	1	29028110	DATE
dpc-1882	207	1	17	CARDINAL
dpc-1882	208	1	garbe c	PERSON
dpc-1882	208	2	keim u	PERSON
dpc-1882	209	1	american joint committee	ORG
dpc-1882	209	2	8	CARDINAL
dpc-1882	209	3	3	CARDINAL
dpc-1882	210	1	j clin oncol	PERSON
dpc-1882	211	1	2020;38(22):2543-2551	DATE
dpc-1882	213	1	32530760	DATE
dpc-1882	214	1	18	CARDINAL
dpc-1882	215	1	michielin o	PERSON
dpc-1882	215	2	van akkooi	PERSON
dpc-1882	216	1	the esmo guidelines committee	ORG
dpc-1882	217	1	ann oncol	PERSON
dpc-1882	218	1	2020;31(11):1449-1461	CARDINAL
dpc-1882	218	2	doi:10.1016	GPE
dpc-1882	218	3	j. annonc.2020.07.005.	PERSON
dpc-1882	219	1	32763452	DATE
dpc-1882	221	1	2021;11(s1	CARDINAL
dpc-1882	221	2	5 19	DATE
dpc-1882	222	1	owen cn	PERSON
dpc-1882	223	1	ann oncol	PERSON
dpc-1882	224	1	2020;31(8):1075-1082	DATE
dpc-1882	225	1	doi:10.1016/j. annonc.2020.04.471	ORG
dpc-1882	226	1	pmid	PERSON
dpc-1882	226	2	32387454	CARDINAL
dpc-1882	227	1	20	CARDINAL
dpc-1882	228	1	bhave p	PERSON
dpc-1882	228	2	pallan l	ORG
dpc-1882	228	3	atkinson	PERSON
dpc-1882	230	1	jco	PERSON
dpc-1882	231	1	2020;38(15_suppl):10016-10016	DATE
dpc-1882	232	1	jco.2020.38.15_suppl.10016	PERSON
dpc-1882	232	2	21	DATE
dpc-1882	233	1	bhave p	PERSON
dpc-1882	233	2	pallan l	PERSON
dpc-1882	234	1	british journal	ORG
dpc-1882	235	1	2021;124(3):574	CARDINAL
dpc-1882	236	1	doi:10.1038	ORG
dpc-1882	236	2	33087895	CARDINAL
dpc-1882	237	1	22	CARDINAL
dpc-1882	238	1	1325-mg/keynote-054	CARDINAL
dpc-1882	238	2	3	CARDINAL
dpc-1882	238	3	pembrolizumab	PERSON
dpc-1882	240	1	july 13	DATE
dpc-1882	240	2	2021	DATE
dpc-1882	242	1	menzies	PERSON
dpc-1882	242	2	amaria rn	PERSON
dpc-1882	242	3	ea	CARDINAL
dpc-1882	245	1	2021;27(2):301	CARDINAL
dpc-1882	246	1	doi:10.1038	ORG
dpc-1882	246	2	33558722	DATE
dpc-1882	247	1	1	CARDINAL
dpc-1882	247	2	5-1882	DATE